首页> 外文OA文献 >PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)

【2h】

PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)

机译：PUK11索非那新5毫克和索非那新10毫克与托勒他定ER 4毫克在过度活性膀胱（OAB）药物治疗患者中的成本效益分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Cardozo L; Thorpe A; Grishchenko M; Sidhu MK;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. [J] . Speakman M, Khullar V, Mundy A, Current medical research and opinion . 2008,第8期

机译：与托特替汀治疗过度活性膀胱综合征相比，每日索尔替尼酸的成本实用性分析。
2. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service [J] . Linda Cardozo Andrew Thorpe Juliet Warner, Linda Cardozo Andrew Thorpe Juliet Warner BJU International . 2010,第4期

机译：在英国国家卫生服务局治疗索非那定与非索罗定，奥昔布宁立即释放，丙氧维林，托特罗定延长释放和托特罗定立即释放在膀胱过度活动症患者中的成本效益
3. THE COST-EFFECTIVENESS OF SOLIFENACIN VS FESOTERODINE, OXYBUTYNIN IMMEDIATE-RELEASE, PROPIVERINE, TOLTERODINE EXTENDED-RELEASE AND TOLTERODINE IMMEDIATE-RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UK NATIONAL HEALTH SERVICE [J] . Juliet L. Warner BJU International . 2010,第4期

机译：索非那宁比索非丁定，奥昔布宁立即释放，异丙肾上腺素，托罗替丁延长释放和托罗替丁立即释放在英国国家卫生服务部门活动过度的患者中的成本效益
4. Use of Electrical Stimulation of the Posterior Tibial Nerve in Patients with Bladder Hyperactivity as a Substitute for Pharmacological Therapy based on Solifenacin Succinate and Oxybutynin Hyloridrate [C] . Fabiana Bianchi Perez, Jose Natal de Souza, Nathalia Cristina Rosa, International Conference on Biomedical Electronics and Devices . 2016

机译：基于Solifencin琥珀酸盐和oxybutynin Hyloridrate的药理学治疗患者膀胱多动患者后胫骨神经电刺激的使用
5. K+ Channels and Beta3 adrenergic receptors as new pharmacological targets for overactive bladder treatment. [D] . Afeli, Serge Amani Yao. 2013

机译：K +通道和Beta3肾上腺素能受体是膀胱过度活跃症治疗的新药理靶标。
6. Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study [O] . David Castro-Diaz, Pilar Miranda, Francisco Sanchez-Ballester, 2012

机译：据报道对患者的剂量和衰老影响从首次使用托特罗定ER过度膀胱治疗转为非索罗定的治疗获益：一项观察性和回顾性研究的事后分析
7. PUK11 UPDATED ECONOMIC ANALYSIS OF FESOTERODINE RELATIVE TO TOLTERODINE AND SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER: THE SWEDISH PERSPECTIVE [O] . Lee R., Snedecor S.J., Kvasz M.G., 2011

机译：PUK11有关替托罗定和索非那宁治疗过活性膀胱的费斯托尔定的最新经济分析：瑞典语观点

PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)

著录项

引文网络

相似文献

相关主题

期刊订阅